{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:10:48Z","timestamp":1776424248368,"version":"3.51.2"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1124\/dmd.123.001425","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T18:32:14Z","timestamp":1689791534000},"page":"1428-1435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen"],"prefix":"10.1016","volume":"51","author":[{"given":"Shunji","family":"Imai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumpei","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutomi","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001425_bib1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.coph.2005.07.001","article-title":"Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers","volume":"5","author":"Amantana","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1124\/dmd.123.001425_bib2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/bc070060v","article-title":"Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate","volume":"18","author":"Amantana","year":"2007","journal-title":"Bioconjug Chem"},{"key":"10.1124\/dmd.123.001425_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/biomedicines6010002","article-title":"The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders","volume":"6","author":"Aupy","year":"2017","journal-title":"Biomedicines"},{"key":"10.1124\/dmd.123.001425_bib4","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/ph15080909","article-title":"The Medicinal Chemistry of Artificial Nucleic Acids and Therapeutic Oligonucleotides","volume":"15","author":"Bege","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/dmd.123.001425_bib5","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3109\/03602538409033558","article-title":"Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm","volume":"15","author":"Boxenbaum","year":"1984","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.123.001425_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-013319-2.50006-1","article-title":"Interspecies pharmacokinetic scaling, biological design and neoteny","volume":"19","author":"Boxenbaum","year":"1990","journal-title":"Adv Drug Res"},{"key":"10.1124\/dmd.123.001425_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-013320-8.50005-8","article-title":"Extrapolation of toxicological and pharmacological data from animals to humans","volume":"20","author":"Chappell","year":"1991","journal-title":"Adv Drug Res"},{"key":"10.1124\/dmd.123.001425_bib8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","article-title":"Safety, Tolerability, and Efficacy of Viltolarsen in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 skipping: A Phase 2 Randomized Clinical Trial","volume":"77","author":"Clemens","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1124\/dmd.123.001425_bib9","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s40262-020-00890-2","article-title":"The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties","volume":"59","author":"Cristea","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001425_bib10","article-title":"RNA therapeutics in the clinic","volume":"8","author":"Curreri","year":"2022","journal-title":"Bioeng Transl Med"},{"key":"10.1124\/dmd.123.001425_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ki.1997.327","article-title":"A method for accurate measurement of GFR in conscious, spontaneously voiding rats","volume":"52","author":"de Vries","year":"1997","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.123.001425_bib12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14712598.2013.774366","article-title":"Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides","volume":"13","author":"Dirin","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"10.1124\/dmd.123.001425_bib13","first-page":"91","article-title":"Effect of Different Fiber Sources as Additives to Wet Food for Beagle Dogs on Diet Acceptance, Digestibility, and Fecal Quality","volume":"10","author":"El-Wahab","year":"2023","journal-title":"Vet Sci"},{"key":"10.1124\/dmd.123.001425_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1517\/17425250902877680","article-title":"Antisense oligonucleotide pharmacokinetics and metabolism","volume":"5","author":"Geary","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001425_bib15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1124\/dmd.31.11.1419","article-title":"Pharmacokinetics of a tumor necrosis factor-\u03b1 phosphorothioate 2\u2032-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species","volume":"31","author":"Geary","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001425_bib16","unstructured":"Highlights of prescribing information\/Exondys 51 (eteplirsen) injection, for intravenous use\/Initial U.S. Approval: 2016\/Revised: 1\/2022."},{"key":"10.1124\/dmd.123.001425_bib17","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1292\/jvms.14-0218","article-title":"Estimation of glomerular filtration rate in cynomolgus monkeys (Macaca fascicularis)","volume":"76","author":"Iwama","year":"2014","journal-title":"J Vet Med Sci"},{"key":"10.1124\/dmd.123.001425_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0713","article-title":"Systemic administration of the antisense oligonucleotide NS-065\/NCNP-01 for skipping of exon 53 in patients with Duchenne muscular dystrophy","volume":"10","author":"Komaki","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1124\/dmd.123.001425_bib19","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1124\/dmd.123.001425_bib20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1056-8719(99)00016-7","article-title":"Measurement of glomerular filtration rate and effective renal plasma flow in the conscious beagle dog by single intravenous bolus of iohexol and p-aminohippuric acid","volume":"41","author":"Laroute","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.123.001425_bib21","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm897","article-title":"Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse","volume":"9","author":"Lu","year":"2003","journal-title":"Nat Med"},{"key":"10.1124\/dmd.123.001425_bib22","doi-asserted-by":"crossref","first-page":"F886","DOI":"10.1152\/ajprenal.00134.2001","article-title":"Age dependency of renal function in CD-1 mice","volume":"282","author":"Luippold","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/dmd.123.001425_bib23","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1089\/nat.2011.0299","article-title":"Pharmacokinetic allometric scaling of oligonucleotides","volume":"21","author":"Mahmood","year":"2011","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.123.001425_bib24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/jvim.15561","article-title":"Clinical utility of estimation of glomerular filtration rate in dogs","volume":"34","author":"McKenna","year":"2020","journal-title":"J Vet Intern Med"},{"key":"10.1124\/dmd.123.001425_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/nat.2017.0709","article-title":"Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver","volume":"28","author":"Miller","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.123.001425_bib26","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1089\/nat.2020.0911","article-title":"Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides","volume":"31","author":"Nanavati","year":"2021","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.123.001425_bib27","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/dmd.119.087395","article-title":"Metabolism and Disposition of Volanesorsen, a 2\u2032-O-(2 methoxyethyl) Antisense Oligonucleotide, Across Species","volume":"47","author":"Post","year":"2019","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001425_bib28","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","article-title":"Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence","volume":"226","author":"Pramono","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1124\/dmd.123.001425_bib29","first-page":"648","article-title":"The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy","volume":"11","author":"Reid","year":"2021","journal-title":"Life (Basel)"},{"key":"10.1124\/dmd.123.001425_bib30","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1177\/1091581811403505","article-title":"Repeat-dose toxicology evaluation in cynomolgus monkeys of AVI-4658, a phosphorodiamidate morpholino oligomer (PMO) drug for the treatment of Duchenne muscular dystrophy","volume":"30","author":"Sazani","year":"2011","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.123.001425_bib31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/17425255.2021.1992382","article-title":"Antisense oligonucleotides: absorption, distribution, metabolism, and excretion","volume":"17","author":"Shadid","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001425_bib32","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino antisense oligomers: design, preparation, and properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1124\/dmd.123.001425_bib33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/nat.2022.0054","article-title":"Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs","volume":"33","author":"Takakusa","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1124\/dmd.123.001425_bib34","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.107.016188","article-title":"Interspecies prediction of human drug clearance based on scaling data from one or two animal species","volume":"35","author":"Tang","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001425_bib35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","article-title":"Pharmacokinetics and Clinical Pharmacology Considerations of GalNAc3-Conjugated Antisense Oligonucleotides","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001425_bib36","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2018.09.017","article-title":"NS-065\/NCNP-01: An Antisense Oligonucleotide for Potential Treatment of Exon 53 Skipping in Duchenne Muscular Dystrophy","volume":"13","author":"Watanabe","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.123.001425_bib37","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/mtna.2014.69","article-title":"Predictive dose-based estimation of systemic exposure multiples in mouse and monkey relative to human for antisense oligonucleotides with 2\u2032-O-(2-methoxyethyl) modifications","volume":"4","author":"Yu","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1124\/dmd.123.001425_bib38","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1124\/dmd.106.012401","article-title":"Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100","volume":"35","author":"Yu","year":"2007","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:05:46Z","timestamp":1739955946000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0090955624010729"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001425","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prediction of Human Pharmacokinetics of Phosphorodiamidate Morpholino Oligonucleotides in Duchenne Muscular Dystrophy Patients Using Viltolarsen","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}